Literature DB >> 25142818

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

R Rahmé1, X Thomas2, C Recher3, N Vey4, J Delaunay5, E Deconinck6, P Hirsch7, D Bordessoule8, J-B Micol9, A Stamatoullas10, C Mariette11, C Pautas12, P Bories13, J-P Marolleau14, M Hunault-Berger15, N Fegueux16, E Raffoux17, H Dombret17, L Degos17, P Fenaux1, L Adès1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25142818     DOI： 10.1038/leu.2014.240

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Massimo Breccia; Eugenio Gallo; Alessandro Rambaldi; Francesca Paoloni; Giuseppe Fioritoni; Felicetto Ferrara; Giorgina Specchia; Giuseppe Cimino; Daniela Diverio; Erika Borlenghi; Giovanni Martinelli; Francesco Di Raimondo; Eros Di Bona; Paola Fazi; Antonio Peta; Alberto Bosi; Angelo M Carella; Francesco Fabbiano; Enrico M Pogliani; Maria C Petti; Sergio Amadori; Franco Mandelli
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

2.  Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Authors:  Lionel Adès; Sylvie Chevret; Emmanuel Raffoux; Stephane de Botton; Agnes Guerci; Arnaud Pigneux; Anne Marie Stoppa; Thierry Lamy; Francoise Rigal-Huguet; Anne Vekhoff; Sandrine Meyer-Monard; Frederic Maloisel; Eric Deconinck; Augustin Ferrant; Xavier Thomas; Nathalie Fegueux; Christine Chomienne; Herve Dombret; Laurent Degos; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

3.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Authors:  Miguel A Sanz; Pau Montesinos; Chelo Rayón; Alexandra Holowiecka; Javier de la Serna; Gustavo Milone; Elena de Lisa; Salut Brunet; Vicente Rubio; José M Ribera; Concha Rivas; Isabel Krsnik; Juan Bergua; José González; Joaquín Díaz-Mediavilla; Rafael Rojas; Félix Manso; Gert Ossenkoppele; José D González; Bob Lowenberg
Journal:  Blood       Date:  2010-04-14       Impact factor: 22.113

4.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Authors:  Jae H Park; Baozhen Qiao; Katherine S Panageas; Maria J Schymura; Joseph G Jurcic; Todd L Rosenblat; Jessica K Altman; Dan Douer; Jacob M Rowe; Martin S Tallman
Journal:  Blood       Date:  2011-06-08       Impact factor: 22.113

5.  Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study.

Authors:  Kristjan Paulson; Anna Serebrin; Pascal Lambert; Julie Bergeron; Janeve Everett; Andrea Kew; David Jones; Salah Mahmud; Catherine Meloche; Mitchell Sabloff; Ismail Sharif; John Storring; Donna Turner; Matthew D Seftel
Journal:  Br J Haematol       Date:  2014-04-30       Impact factor: 6.998

6.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Authors:  S Lehmann; A Ravn; L Carlsson; P Antunovic; S Deneberg; L Möllgård; A Rangert Derolf; D Stockelberg; U Tidefelt; A Wahlin; L Wennström; M Höglund; G Juliusson
Journal:  Leukemia       Date:  2011-04-19       Impact factor: 11.528

7.  Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

Authors:  James Scott McClellan; Holbrook E Kohrt; Steven Coutre; Jason R Gotlib; Ravindra Majeti; Ash A Alizadeh; Bruno C Medeiros
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

8.  Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

Authors:  Jessica K Altman; Alfred Rademaker; Elizabeth Cull; Bing Bing Weitner; Yishai Ofran; Todd L Rosenblat; Augustin Haidau; Jae H Park; Sharona Lee Ram; James M Orsini; Sonia Sandhu; Rosalind Catchatourian; Steven M Trifilio; Nelly G Adel; Olga Frankfurt; Eytan M Stein; George Mallios; Tony Deblasio; Joseph G Jurcic; Stephen Nimer; Loann C Peterson; Hau C Kwaan; Jacob M Rowe; Dan Douer; Martin S Tallman
Journal:  Leuk Res       Date:  2013-06-14       Impact factor: 3.156

9.  Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

Authors:  S De Botton; H Dombret; M Sanz; J S Miguel; D Caillot; R Zittoun; M Gardembas; A Stamatoulas; E Condé; A Guerci; C Gardin; K Geiser; D C Makhoul; O Reman; J de la Serna; F Lefrere; C Chomienne; C Chastang; L Degos; P Fenaux
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

10.  Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

Authors:  Charikleia Kelaidi; Sylvie Chevret; Stéphane De Botton; Emmanuel Raffoux; Agnès Guerci; Xavier Thomas; Arnaud Pigneux; Thierry Lamy; Françoise Rigal-Huguet; Sandrine Meyer-Monard; Patrice Chevallier; Frédéric Maloisel; Erick Deconinck; Augustin Ferrant; Nathalie Fegueux; Norbert Ifrah; Miguel Sanz; Hervé Dombret; Pierre Fenaux; Lionel Adès
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544
View more
  11 in total

1.  Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Authors:  Simon Mantha; Debra A Goldman; Sean M Devlin; Ju-Whei Lee; Diana Zannino; Marnie Collins; Dan Douer; Harry J Iland; Mark R Litzow; Eytan M Stein; Frederick R Appelbaum; Richard A Larson; Richard Stone; Bayard L Powell; Susan Geyer; Kristina Laumann; Jacob M Rowe; Harry Erba; Steven Coutre; Megan Othus; Jae H Park; Peter H Wiernik; Martin S Tallman
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

2.  Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Authors:  Ramy Rahmé; Lionel Ades; Xavier Thomas; Agnès Guerci-Bresler; Arnaud Pigneux; Norbert Vey; Emmanuel Raffoux; Sylvie Castaigne; Olivier Spertini; Sebastian Wittnebel; Jean Pierre Marolleau; Gandhi Damaj; Dominique Bordessoule; Julie Lejeune; Sylvie Chevret; Pierre Fenaux
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 9.941

3.  Prompt all-trans retinoic acid administration and early death in acute promyelocytic leukemia: what does the evidence say?

Authors:  A Rashidi; S I Fisher
Journal:  Leukemia       Date:  2014-09-17       Impact factor: 11.528

4.  Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.

Authors:  Gi-June Min; Byung-Sik Cho; Sung-Soo Park; Silvia Park; Young-Woo Jeon; Seung-Ah Yahng; Seung-Hawn Shin; Jae-Ho Yoon; Sung-Eun Lee; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong Wook Lee; Hee-Je Kim
Journal:  Ann Hematol       Date:  2020-04-08       Impact factor: 3.673

5.  Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.

Authors:  Hisayuki Yokoyama; Naoto Takahashi; Yuna Katsuoka; Mitsue Inomata; Toshihiro Ito; Kuniaki Meguro; Yoshihiro Kameoka; Riko Tsumanuma; Kazunori Murai; Hideyoshi Noji; Kenichi Ishizawa; Shigeki Ito; Yasushi Onishi; Hideo Harigae
Journal:  Int J Hematol       Date:  2017-02-07       Impact factor: 2.490

Review 6.  Acute promyelocytic leukemia: preventing early complications and late toxicities.

Authors:  Sameem Abedin; Jessica K Altman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Authors:  Lionel Adès; Xavier Thomas; Agnes Guerci Bresler; Emmanuel Raffoux; Olivier Spertini; Norbert Vey; Tony Marchand; Christian Récher; Arnaud Pigneux; Stephane Girault; Eric Deconinck; Claude Gardin; Olivier Tournilhac; Jean Francois Lambert; Patrice Chevallier; Stephane de Botton; Julie Lejeune; Hervé Dombret; Sylvie Chevret; Pierre Fenaux
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

8.  All-trans retinoic acid 45 mg/m2 is superior to 25 mg/m2 as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting.

Authors:  Xinhui Zhang; Shanglong Feng; Jin Xu; Na Zhao; Xing Hu; Li Zhou; Juan Tong; Lei Xue; Lei Zhang; Yongsheng Han; Xingbing Wang; Liangquan Geng; Xiaoyu Zhu; Baolin Tang; Huilan Liu; Weibo Zhu; Xiaoyan Cai; Xin Liu; Zimin Sun; Changcheng Zheng
Journal:  Blood Cancer J       Date:  2021-01-29       Impact factor: 11.037

9.  Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration.

Authors:  Mary Nauffal; Lillian Werner; Jian Ni; Richard M Stone; Daniel J DeAngelo; Anne M McDonnell
Journal:  Leuk Res Rep       Date:  2019-11-27

10.  Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.

Authors:  Sabine Kayser; Richard F Schlenk; Delphine Lebon; Martin Carre; Katharina S Götze; Friedrich Stölzel; Ana Berceanu; Kerstin Schäfer-Eckart; Pierre Peterlin; Yosr Hicheri; Ramy Rahme; Emmanuel Raffoux; Fatiha Chermat; Stefan W Krause; Walter E Aulitzky; Sophie Rigaudeau; Richard Noppeney; Celine Berthon; Martin Görner; Edgar Jost; Philippe Carassou; Ulrich Keller; Corentin Orvain; Thorsten Braun; Colombe Saillard; Ali Arar; Volker Kunzmann; Mathieu Wemeau; Maike De Wit; Dirk Niemann; Caroline Bonmati; Carsten Schwänen; Julie Abraham; Ahmad Aljijakli; Stephanie Haiat; Alwin Krämer; Albrecht Reichle; Martina Gnadler; Christophe Willekens; Karsten Spiekermann; Wolfgang Hiddemann; Carsten Müller-Tidow; Christian Thiede; Christoph Röllig; Hubert Serve; Martin Bornhäuser; Claudia D Baldus; Eva Lengfelder; Pierre Fenaux; Uwe Platzbecker; Lionel Adès
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.